Facilitators and Barriers in AI Medical Imaging Implementation: A Systematic Review

By Staff Writer

July 22, 2025

What are the main AI medical imaging barriers and how do they impact real-world integration in healthcare?

Successfully adopting AI in routine medical imaging requires overcoming a complex set of obstacles while leveraging facilitators to streamline the process. A recently published in-depth review addresses the most critical AI medical imaging barriers—such as technological reliability, medicolegal concerns, and workflow alignment—and examines proven strategies that enable smooth adoption in clinical settings.

Summary of Findings

Integrating artificial intelligence into medical imaging brings both transformative potential and several challenges. A systematic review of 38 studies highlights that optimal implementation revolves around:

  • Workflow integration: Seamless compatibility with existing processes drives success.
  • Clinician attitudes and training: Ongoing education and positive engagement facilitate acceptance.
  • Technological reliability: Robust, interoperable solutions are crucial; gaps here become significant AI medical imaging barriers.
  • Medicolegal and explainability concerns: Legal uncertainties and unclear AI recommendations often slow down real-world use.

For a detailed look at the empirical evidence and recommendations, refer to this comprehensive JMIR analysis of facilitators and barriers in medical imaging AI.

Key Insights

  • Integration with clinical workflow ensures AI tools enhance efficiency rather than disrupt established routines.
  • Stakeholder engagement—including active clinician feedback and leadership support—emerges as a vital facilitator.
  • Human-centered design and robust user training bridge the gap between technology and clinical needs.
  • Conversely, insufficient explainability of AI outputs and concern about liability remain leading AI medical imaging barriers, particularly in highly regulated healthcare environments.
  • Only about one-third of included studies prioritized end-user feedback, highlighting opportunities for more patient- and provider-centric design approaches (see more in the Journal of Medical Internet Research report).

Implications for Health Economics and Decision-Making

Understanding both facilitators and barriers to AI implementation in medical imaging directly informs health economic strategies and outcomes-based planning. Specifically:

  • Healthcare organizations can prioritize solutions proven to integrate well with clinical workflows, lowering the risk of failed investments.
  • Awareness of medicolegal and transparency barriers helps forecast potential liability costs and regulatory hurdles.
  • Long-term cost-effectiveness depends not just on the technology’s accuracy, but also on sustained clinician engagement and feedback.

Frequently Asked Questions

What are the most significant facilitators for AI adoption in medical imaging?
Key facilitators include seamless workflow integration, targeted user training, perceived clinical usefulness of AI tools, and active engagement from clinicians and leadership.

Which barriers most frequently impede AI implementation in healthcare imaging?
The most common AI medical imaging barriers are technological reliability challenges, limited explainability of AI decisions, medicolegal risks, and poor alignment with real-world clinical needs.

How can healthcare leaders overcome AI adoption barriers and accelerate benefits?
By evaluating solutions for proven real-world performance, investing in comprehensive clinician training, and proactively addressing both technical and policy-related hurdles, healthcare organizations can foster impactful, sustainable AI integration.

Conclusion

Effectively navigating AI medical imaging barriers is central to maximizing the value of artificial intelligence in clinical practice. Healthcare decision-makers should combine evidence-based workflow assessments, stakeholder involvement, and targeted training to create sustainable, trustworthy AI solutions. For the latest research and in-depth recommendations, explore the full JMIR report on AI adoption barriers and facilitators in medical imaging.

Reference url

Recent Posts

Rare Medications Coverage in the Netherlands: Price Reductions Required

By Staff Writer

August 15, 2025

Zorginstituut Nederland has announced that two rare disease medications, exagamglogene autotemcel (Casgevy®) and omaveloxolon (Skyclarys®), will only be covered by Dutch basic health insurance if their prices drop significantly. For omaveloxolon, treating Friedreich's ataxia, an 84% price cut is ...
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Disease
Sanofi's rilzabrutinib has received orphan drug designation from the European Medicines Agency for treating IgG4-related disease (IgG4-RD). This reversible covalent Bruton's tyrosine kinase (BTK) inhibitor earned the designation based on promising Phase 2 study results. The findings, presented at...
Strengthening the U.S. Pharmaceutical Supply Chain: Establishing a Strategic API Reserve
The recent White House executive action introduces the establishment of a Strategic Active Pharmaceutical Ingredients (API) Reserve. This aims to bolster the resilience of the U.S. Pharmaceutical Supply Chain. The directive mandates federal support for domestic production of critical APIs. It inc...